Slide 1: Corporate Presentation Aug 2023
Corporate Presentation Aug 2023
Slide 2: Forward-Looking Statements
Proprietary & Confidential Research Solutions, Inc. 2 Forward-Looking Statements Certain statements in this press release may contain "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be dee
Slide 3: Agenda
Proprietary & Confidential Research Solutions, Inc. 3 1. Introduction 2. What we do 3. Business Model & Opportunity 4. Knowledge Graphs 5. Opportunity 6. Solutions 7. Financials Agenda
Slide 4: Introduction
Introduction
Slide 5: We Empower Research Intensive Organizations to Accelerate Innovation
Proprietary & Confidential Research Solutions, Inc. 5 We Empower Research Intensive Organizations to Accelerate Innovation Innovation Strategy R&D Product Development Post Development • Market Intel • Competitor Intel • IP Analysis • Technology Trends • Scientific Research & Development • Regulatory
Slide 6: What we do
What we do
Slide 7: Solving Information Overload
Proprietary & Confidential Research Solutions, Inc. 7 Solving Information Overload Rapid Exponential Growth in Scientific Journal Publications Data from https://openalex.org/ • Confidence Nothing Is Missed • Speed & Ease • Assistance in Serendipitous Discovery • Access To A Comprehensive Collection
Slide 8: In other words...
Proprietary & Confidential Research Solutions, Inc. 8 In other words... Scientific Research Legal Research Financial Research Articles from Scientific, Technical & Medical (STM) Journals, R&D Efficiency Tools Laws, Legal Cases & Opinions Annual Reports & Financial Market Data
Slide 9: Business Model & Opportunity
Business Model & Opportunity
Slide 10: Growth Through Organic Growth of Current SaaS Products
Proprietary & Confidential Research Solutions, Inc. 10 10 Growth Through Organic Growth of Current SaaS Products • Advanced Discovery Tools • Advanced reporting and knowledge graphs • Entitlement Management • Workflow Solutions For • Key Opinion Leader Identification • Clinical Trials • Competitive
Slide 11: SaaS Platforms and Document Delivery Revenue
Proprietary & Confidential Research Solutions, Inc. 11 SaaS Platforms • Fastest-growing and recurring • High retention rates (>105%) • TTM gross margin 88.0% Document Delivery • Sticky, scalable, repeat revenue • TTM gross margin 24.2% $23.7 $24.8 $26.2 $26.0 $27.2 $26.6 $26.1 $28.0 FY16 FY17 FY18 F
Slide 12: FY24 Q4 and Full Year Pre-Release
Proprietary & Confidential Research Solutions, Inc. 12 FY23 FY24 Gain Platform Revenues $ 6.8 $ 8.7 28% DocDel Revenue $ 26.1 $ 29.0 11% Total Revenues $ 32.9 $ 37.7 14% ARR $ 7.9 $ 9.4 19% Adjusted EBITDA $ (0.4) $ 2.0 636% Cash Flow $ (0.4) $ 3.4 915% FY24 Q4 and Full Year Pre-Release
Slide 13: Able to Serve All Research-Focused Industries
Proprietary & Confidential Research Solutions, Inc. 13 Able to Serve All Research-Focused Industries Data from World Top 2500 R&D Investors 2022 Edition Number of Companies per Region
Slide 14: Competitive Intelligence, Patent Management, Clinical Research
Proprietary & Confidential Research Solutions, Inc. 14 14 Competitive Intelligence Patent Management Clinical Research Medical Liaisons R&D Regulatory Post Market Surveillance Business Development Marketing R&D 26
Slide 15: RSSS TAM FY23 vs FY24+
Proprietary & Confidential Research Solutions, Inc. 15 15 RSSS TAM FY23 < $1B RSSS TAM FY24+ > $4B 27
Slide 16: Innovation Value Chain – Life Sciences
Proprietary & Confidential Research Solutions, Inc. 16 Innovation Value Chain – Life Sciences Competitive Intelligence IP Management Market Intelligence Technology Landscape Literature Search & Discovery Target Identification/ Hypothesis Generation Data Science Translational Science Clinical Researc
Slide 17: Knowledge Graphs
Knowledge Graphs
Slide 18: Graph Databases
Proprietary & Confidential Research Solutions, Inc. 18 Graph Databases 18 A graph database stores relationships in a format known as a triple, composed of a subject, predicate, and object. The subject and the object are called nodes, which store data entities, and the predicate is called an edge, wh
Slide 19: Using AI to Build Knowledge Discovery Systems
Proprietary & Confidential Research Solutions, Inc. 19 Taxonomies/Ontologies NLP, ML, & LLM Knowledge Graphs Specific Use Cases NLP, ML, & LLM NLP, ML, & LLM Using AI to Build Knowledge Discovery Systems
Slide 20: Knowledge Graphs Link Concepts to Enhance Search & Discovery
Knowledge Graphs Link Concepts to Greatly Enhance Search & Discovery Visualization of a network of connections can immediately provide context. At the center of the illustration is Michael Houghton, a Nobel Prize winner in Physiology or Medicine in 2020 for discovering the Hepatitis C virus. Here we
Slide 21: Knowledge Graphs Used to Shortlist Therapies for COVID-19
Knowledge Graphs Were Used to Rapidly Shortlist Therapies for COVID-19 https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00316 Research Solutions Reprints Desk Proprietary & Confidential 17 In early 2020, researchers used a comprehensive Knowledge Graph that looked at 39 types of relationships connec
Slide 22: Opportunity
Opportunity
Slide 23: Innovation Value Chain – Life Sciences
Proprietary & Confidential Research Solutions, Inc. 23 Innovation Value Chain – Life Sciences Competitive Intelligence IP Management Market Intelligence Technology Landscape Literature Search & Discovery Target Identification/ Hypothesis Generation Data Science Translational Science Clinical Researc
Slide 24: Article Galaxy 2021 Literature Access Strategy
Proprietary & Confidential Research Solutions, Inc. 24 Innovation Value Chain – Life Sciences – Article Galaxy (“AG”) 2021 Literature Access Strategy R&D Clinical Development Post Market & Commercial Research Solutions Reprints Desk Proprietary & Confidential 20
Slide 25: AG 2023 + Curedatis + AGR
Proprietary & Confidential Research Solutions, Inc. 25 Innovation Value Chain – Life Sciences – AG 2023 + Curedatis + AGR Literature Search & Management Medical Affairs Regulatory Affairs Pharmacovigilance/ Device Monitoring Strategy R&D Clinical Development Post Market & Commercial Research Solutio
Slide 26: RSSS + ResoluteAI – 2023
Proprietary & Confidential Research Solutions, Inc. 26 Innovation Value Chain – Life Sciences – RSSS + ResoluteAI – 2023 Competitive Intelligence IP Management Market Intelligence Technology Landscape Literature Search & Discovery Translational Science Clinical Research Clinical Operations & Analysi
Slide 27: Solutions
Solutions
Slide 28: RSSS Product Ecosystem: Current Solutions
Proprietary & Confidential Research Solutions, Inc. 28 RSSS Product Ecosystem: Current Solutions Article Galaxy/References & Curedatis Focus of R&D Use Cases Research & Development Systematic Lit. Review Document Delivery Reference Manager Department / Persona Group Typical Innovation Workflow Doc D
Slide 29: Product Ecosystem: Adding ResoluteAI
Proprietary & Confidential Research Solutions, Inc. 29 RSSS Product Ecosystem: By Adding ResoluteAI, We More Completely Address R&D Use Cases As Part of A Workflow Research & Development Systematic Lit. Review Clinical Trial KOL Comp. Landsc. Document Delivery Reference Manager Patents Search Depart
Slide 30: Product Roadmap
Proprietary & Confidential Research Solutions, Inc. 30 Product Roadmap Innovation User Journey Search & Discovery (Document) Delivery Knowledge Management Creation Today Resolute.AI Foundation Nebula RSSS Article Galaxy / References Curedatis
Slide 31: Product Roadmap GTM 3-6 Months After Close
Proprietary & Confidential Research Solutions, Inc. 31 Product Roadmap GTM 3-6 Months After Close Foundation Clinical Research Foundation Key Opinion Leader DocDel integrati on Search Article Galaxy / References Post Market Surveillance Curedatis Innovation User Journey Search & Discovery (Document)
Slide 32: Product Roadmap: Project Orange
Proprietary & Confidential Research Solutions, Inc. 32 Product Roadmap GTM 6 – 24 Months After Closure “Project Orange” GTM 3-6 Months After Closure Foundation Clinical Research Foundation Key Opinion Leader DocDel integrati on Search Article Galaxy / References Post Market Surveillance Curedatis In
Slide 33: RSSS Product Ecosystem – Long Term
Proprietary & Confidential Research Solutions, Inc. 33 RSSS Product Ecosystem – Long Term: Competitive Intelligence Research & Development Clinical Research & Operations IP / Patent Management Business Development Medical Affairs Clinical Trial (Drug) Pipeline Document Delivery Reference Manager Com
Slide 34: Financials
Financials
Slide 35: Revenue Profile
Proprietary & Confidential Research Solutions, Inc. 35 Revenue Profile Platforms • Fastest-growing and recurring • No direct substitute • High retention rates (>105%) • TTM gross margin 88.0% Transactions • Sticky, scalable, repeat revenue • TTM gross margin 24.2% $23.7 $24.8 $26.2 $26.0 $27.2 $26.6
Slide 36: Balance Sheet Supports Growth
Proprietary & Confidential Research Solutions, Inc. 36 Balance Sheet Supports Growth | © 2022 Research Solutions, Inc. All Rights Reserved $ Millions Mar 31, 2023 Jun 30, 2022 Cash and equivalents 12.1 10.6 Accounts receivable 6.8 5.3 Prepaid expenses/royalties 0.4 0.3 Other assets 1.3 0.9 Total Ass
Slide 37: Key Takeaways
Proprietary & Confidential Research Solutions, Inc. 37 Key Takeaways Strategic SaaS Transformation Underway: platform interconnects & extracts highly useful scientific, technical & medical content & data Information Logistics Backbone: transaction business provides multi-million dollar information b
Slide 38: Key Stats
Proprietary & Confidential Research Solutions, Inc. 38 Key Stats Stock Price (5/11/23) $2.10 52 Week Low-High $1.69-$2.40 Avg. Daily Vol. (3 month) 12,737 Shares Out/Diluted* 29.5M/32.4M Insider Holdings* ~29.3% Enterprise Value $49.8M Market Cap $62.0M Employee Count (including full time contractor
Slide 39: Management Team
Proprietary & Confidential Research Solutions, Inc. 39 Management Team Michiel van der Heijden Chief Product Officer Shane Hunt Chief Revenue Officer Rick Salloum Chief Technology Officer Roy W. Olivier CEO & President William Nurthen Chief Financial Officer Scott Ahlberg Chief Operations Officer Jo
Slide 40: For more information, please visit
Proprietary & Confidential Research Solutions, Inc. 40 www.researchsolutions.com For more information, please visit: Investor Relations Contact Three Part Advisors, LLC / Phone: 214-872-2710 Steven Hooser shooser@threepa.com John Beisler jbeisler@threepa.com Contact Us Research Solutions, Inc. / Ema
Slide 41: Appendix
Appendix
Slide 42: Capitalization Table
Proprietary & Confidential Research Solutions, Inc. 42 Capitalization Table * Includes 2.1 million restricted shares issued pursuant to the Company’s Long-Term Equity Bonus Plan (LTEBP). These shares vest in 20% increments at vesting targets ranging between $3.00 and $6.00 per share. For more inform
Slide 43: Quarterly Financial Results
Proprietary & Confidential Research Solutions, Inc. 43 Research Solutions, Inc. (NASDAQ:RSSS) researchsolutions.com Includes Non -GAAP Financial Data Quarterly Financial Results
Slide 44: Quarterly Financial Results
Proprietary & Confidential Research Solutions, Inc. 44 Research Solutions, Inc. (NASDAQ:RSSS) researchsolutions.com Includes Non -GAAP Financial Data Quarterly Financial Results
Slide 45: Quarterly Financial Results Definitions
Proprietary & Confidential Research Solutions, Inc. 45 Quarterly Financial Results 1 Annual Recurring Revenue (Non-GAAP Measure) - the value of contracted platform subscription recurring revenue normalized to a one year period. 2 Customers - the sum of the total quantity of customers per month for e
Slide 46: Product Summaries
Proprietary & Confidential Research Solutions, Inc. 46 Product Summaries Article Galaxy/References: Enables the discovery, access and management of Scientific content published by all the most important scientific publishers Article Galaxy Scholar: does this as well but to address specific needs of
Slide 47: Stock Symbol RSSS
Proprietary & Confidential Research Solutions, Inc. 47 Stock Symbol RSSS